The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TKNO | -31.64% | N/A | N/A | -81% |
| S&P | +12.65% | +91.73% | +13.89% | +57% |
Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.45M | 9.2% |
| Gross Profit | $2.92M | 1581.7% |
| Gross Margin | 27.92% | 30.0% |
| Market Cap | $331.26M | 28.4% |
| Market Cap / Employee | $1.91M | 0.0% |
| Employees | 173 | -18.0% |
| Net Income | -$4.29M | 43.3% |
| EBITDA | -$2.43M | 57.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.20M | -47.9% |
| Accounts Receivable | $5.14M | 11.5% |
| Inventory | 6.9 | -9.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $27.09M | 3.3% |
| Short Term Debt | $1.89M | -56.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.73% | 8.4% |
| Return On Invested Capital | -17.89% | -4.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.27M | 5.1% |
| Operating Free Cash Flow | -$1.88M | 8.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.10 | 3.36 | 3.34 | 4.36 | 47.33% |
| Price to Sales | 6.90 | 11.81 | 7.25 | 6.74 | 320.90% |
| Price to Tangible Book Value | 6.02 | 4.00 | 3.99 | 5.21 | 49.31% |
| Enterprise Value to EBITDA | -62.69 | -131.64 | -156.09 | -110.22 | 829.06% |
| Return on Equity | -31.0% | -28.8% | -27.7% | -22.8% | -32.78% |
| Total Debt | $30.17M | $29.35M | $28.97M | $28.98M | -5.25% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
